Brief: Immunome To Acquire AL102 Phase 3 Asset for the Treatment of Desmoid Tumors From Ayala Pharmaceuticals

Ayala Pharmaceuticals

06/02/2024 14:37

Feb 6 (Reuters) - Ayala Pharmaceuticals Inc  ADXS.PK :
    * IMMUNOME TO ACQUIRE AL102, A PHASE 3 ASSET FOR THE
TREATMENT OF
DESMOID TUMORS, FROM AYALA PHARMACEUTICALS
    * IMMUNOME INC - UNDER DEAL, TO PAY AYALA $20 MILLION IN
CASH &
$30 MILLION IN IMMUNOME COMMON STOCK (VALUED AT 30-DAY VWAP AS
OF FEBRUARY 1, 2024) AT CLOSING
    * IMMUNOME INC - UNDER DEAL, WILL PAY UP TO AN ADDITIONAL
$37.5
MILLION IN DEVELOPMENT AND COMMERCIAL MILESTONE PAYMENTS

Source text for Eikon:  ID:nGNXbJQSPr 
Further company coverage:  ADXS.PK 

 ((Reuters.Briefs@thomsonreuters.com;))